Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors

The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study. We performed a multicenter retrospective real-world analysis of patients with mCRC receiving t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical colorectal cancer 2021-12, Vol.20 (4), p.342-349
Main Authors: Stavraka, Chara, Pouptsis, Athanasios, Synowiec, Alicja, Angelis, Vasileios, Satterthwaite, Liyana, Khan, Sam, Chauhan, Meera, Holden, Chloe, Young, Sally, Karampera, Christina, Martinou, Maria, Mills-Baldock, Tina, Baxter, Mark, Barry, Ainsley, Eccles, Bryony, Iveson, Timothy, Shiu, Kai-Keen, Hill, Mark, Abdel-Raouf, Sherif, Graham, Janet Shirley, Thomas, Anne, Ross, Paul J.
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Colorectal Neoplasms - drug therapy
Humans
Lonsurf
Neutropenia
Prognosis
Pyrrolidines
Real-world evidence
Retrospective Studies
TAS-102
Thymine
Treatment outcomes
Trifluridine - adverse effects
Uracil - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study. We performed a multicenter retrospective real-world analysis of patients with mCRC receiving trifluridine/tipiracil between 2016 and 2019 in eight cancer centers across the United Kingdom. A total of 236 patients were included with median age of 69 years. All patients had received at least 2 lines of fluoropyrimidine-based chemotherapy doublet with oxaliplatin or irinotecan. About 10% of patients had ECOG ≥ 2. Median duration of trifluridine/tipiracil treatment was 3 months with an ORR of 2.1% and disease control rate of 21.6%. Median OS was 7.6 and median PFS 3.3 months. A dose reduction was required in 27% of patients, while 7.6% discontinued treatment due to toxicity. The most common grade 3 toxicities were neutropenia (34%), fatigue (10%), anemia (9%) and febrile neutropenia (5%). Baseline NLR
ISSN:1533-0028
1938-0674
DOI:10.1016/j.clcc.2021.09.009